Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailThe clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Reginster, Jean-Yves ULg

in Annals of the Rheumatic Diseases (2009, June), 68(S3), 667

Detailed reference viewed: 22 (14 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of nonadherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Bruyère, Olivier ULg et al

in Value in Health (2009, October), 12(7), 444

Detailed reference viewed: 38 (13 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2012), 15(5), 604-12

OBJECTIVES: Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to ... [more ▼]

OBJECTIVES: Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of improving patient adherence by using hypothetical behavioral interventions. METHODS: A previously validated Markov microsimulation model was adapted to the Irish setting to estimate lifetime costs and outcomes (fractures and quality-adjusted life-year [QALY]) for three adherence scenarios: no treatment, real-world adherence, and full adherence over 3 years. The real-world scenario employed adherence and persistence data from the Irish Health Services Executive-Primary Care Reimbursement Services pharmacy claims database. We also investigated the cost-effectiveness of hypothetical behavioral interventions to improve medication adherence (according to their cost and effect on adherence). RESULTS: The number of fractures prevented and the QALY gain obtained at real-world adherence levels represented only 57% and 56% of those expected with full adherence, respectively. The costs per QALY gained of real-world adherence and of full adherence compared with no treatment were estimated at euro 11,834 and euro 6,341, respectively. An intervention to improve adherence by 25% would result in an incremental cost-effectiveness ratio of euro 11,511 per QALY and euro 54,182 per QALY, compared with real-world adherence, if the intervention cost an additional euro 50 and euro 100 per year, respectively. DISCUSSION: Poor adherence with osteoporosis medications results in around a 50% reduction in the potential benefits observed in clinical trials and a doubling of the cost per QALY gained from these medications. Depending on their costs and outcomes, programs to improve adherence have the potential to be an efficient use of resources. [less ▲]

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of poor adherence with osteoporosis medications in Ireland
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

in Value in Health (2011), 14

Detailed reference viewed: 25 (8 ULg)
Full Text
Peer Reviewed
See detailClinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.
Abizaid, A.; Costa, M. A.; Centemero, M. et al

in Circulation (2001), 104(5), 533-8

BACKGROUND: Our aims were to compare coronary artery bypass grafting (CABG) and stenting for the treatment of diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization ... [more ▼]

BACKGROUND: Our aims were to compare coronary artery bypass grafting (CABG) and stenting for the treatment of diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization Therapy Study (ARTS) trial and to determine the costs of these 2 treatment strategies. METHODS AND RESULTS: Patients (n=1205) were randomly assigned to stent implantation (n=600; diabetic, 112) or CABG (n=605; diabetic, 96). Costs per patient were calculated as the product of each patient's use of resources and the corresponding unit costs. Baseline characteristics were similar between the groups. At 1 year, diabetic patients treated with stenting had the lowest event-free survival rate (63.4%) because of a higher incidence of repeat revascularization compared with both diabetic patients treated with CABG (84.4%, P<0.001) and nondiabetic patients treated with stents (76.2%, P=0.04). Conversely, diabetic and nondiabetic patients experienced similar 1-year event-free survival rates when treated with CABG (84.4% and 88.4%). The total 1-year costs for stenting and CABG in diabetic patients were $12 855 and $16 585 (P<0.001) and in the nondiabetic groups, $10 164 for stenting and $13 082 for surgery. CONCLUSIONS: Multivessel diabetic patients treated with stenting had a worse 1-year outcome than patients assigned to CABG or nondiabetics treated with stenting. The strategy of stenting was less costly than CABG, however, regardless of diabetic status. [less ▲]

Detailed reference viewed: 1 (0 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic implications of non-adherence with osteoporosis medications in Ireland
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

Conference (2011, November)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailCLINICAL AND FUNCTIONAL CHARACTERISTICS OF NONAGENARIANS HOSPITALIZED IN A GERIATRIC UNIT: A DESCRIPTIVE STUDY
Petermans, Jean ULg; Mathieu, Sandrine; ALLEPAERTS, Sophie ULg et al

in Journal of Aging Research and Clinical Practice (2013), 2(3), 303-309

Detailed reference viewed: 46 (12 ULg)
Peer Reviewed
See detailClinical and functional investigation in an experimental model of chronic bronchitis in dogs
Bolognin, M.; Bourguignon, V.; Hofman, A. C. et al

in 18th ECVIM Meeting - Gent - Belgique - 2-5 septembre 2008 (2008, September 02)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailClinical and functional responses to inhaled albuterol, ipratropium bromide and combination of both in ascaris suum-sensitized cats with allergen-induced bronchospasm
Leemans, Jérôme ULg; Kirschvink, N.; Cambier, Carole ULg et al

in Proceedings: 26th Annual Symposium of the Veterinary and Comparative Respiratory Society (2008)

Detailed reference viewed: 30 (3 ULg)
Peer Reviewed
See detailClinical and functional responses to inhaled salmeterol in experimentally asthmatic cats with allergen-induced bronchospasm
Bernaerts, Frederique ULg; Leemans, Jérôme ULg; Kirschvink, N. et al

in Proceedings : 18th Congress European College of Veterinary Internal Medicine – companion animals (2008)

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailClinical and genetic aspects of Familial Isolated Pituitary Adenomas
Vasilev, V.; Daly, A.; Naves, L. et al

in Clinics (2012)

Detailed reference viewed: 29 (6 ULg)
See detailClinical and genetic aspects of MEN1 and related diseases : a 3 year experience based on the French-Belgian Study group on MEN1
Calender, A.; Murat, A.; Carpentier, B. et al

in 6th International Workshop on Multiple Endocrine Neoplasia and Von Hippel-Lindau Disease (1997)

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirowa, M et al

in Abstract book - Aspiring excellence : Pituitary expert forum (2012)

Detailed reference viewed: 15 (2 ULg)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirova, M et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirowa, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 40 (5 ULg)
Full Text
Peer Reviewed
See detailClinical and genetic features of familial pituitary adenomas.
Daly, Adrian ULg; Jaffrain-Rea, M. L.; Beckers, Albert ULg

in Hormone & Metabolic Research (2005), 37(6), 347-54

Inherited or familial pituitary tumor syndromes such as multiple endocrine neoplasia type 1 and Carney complex provide an important insight into the genetics and molecular pathology of endocrine cancers ... [more ▼]

Inherited or familial pituitary tumor syndromes such as multiple endocrine neoplasia type 1 and Carney complex provide an important insight into the genetics and molecular pathology of endocrine cancers. Our understanding of these conditions is expanding rapidly due to the identification of the genes and proteins affected and the availability of murine knockout models. The successes achieved to date in understanding multiple endocrine neoplasia type 1 and Carney complex have helped in the identification and study of new inherited pituitary tumor syndromes such as isolated familial somatotropinomas. This review assesses the current status of research into the clinical features, genetics and molecular pathologies of multiple endocrine neoplasia type 1, Carney complex, and isolated familial somatotropinomas, and details ongoing work to delineate familial isolated pituitary adenomas, a potentially new clinical entity. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailClinical and genetic studies in patients with Pituitary/Parathyroid variant of MEN1 without MEN1 gene mutation : the French GENEM collaborative study
VALDES SOCIN, Hernan Gonzalo ULg; Burlacu, C; Delemer, B et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 19 (1 ULg)
See detailClinical and genom-wide linkage studies of a multigénérational family with acromegaly and the exclusion of requiem gene
Khoo, S. K.; Chan, S.; Pendek, R. et al

in The Endocrine Society's 84th Annual Meeting - Abstract book (2002)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailClinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.
Berardesca, Enzo; Iorizzo, Matilde; Abril, Elva et al

in Journal of Cosmetic Dermatology (2012), 11(1), 37-41

Background Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of ... [more ▼]

Background Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of skin inflammation. Aim To assess the benefit of topical applications of a new product (P-3075). Patients/Methods A randomized, multicenter, double-blind, placebo-controlled, parallel-group, pilot study was carried out to evaluate the efficacy and tolerability of a cream (P-3075) based on 5% potassium azeloyl diglycinate (PAD, Azeloglicina((R)) ) and 1% hydroxypropyl chitosan (HPCH). Forty-two patients (rosacea stages I and II) were enrolled and randomized, 28 in the P-3075 group and 14 in the placebo group. They were asked to apply the cream twice daily for 4 weeks. The main assessments were the objective quantification of erythema and skin hydration using the Mexameter((R)) and Corneometer((R)) devices, respectively. Clinical signs and symptoms were evaluated on a four-point scale. Results The P-3075 cream applied for 28 days was effective in skin protection by reducing erythema, evaluated both instrumentally and clinically. In addition, the clinical assessments of other symptoms such as flushing, stinging, and burning supported the beneficial effect of the P-3075 cream. Conclusions The anti-inflammatory and moisturizing effects of potassium azeloyl diglycinate combined with the protective properties of HPCH allow the new product to be a good candidate for controlling signs and symptoms of rosacea. [less ▲]

Detailed reference viewed: 36 (5 ULg)
Full Text
Peer Reviewed
See detailClinical and mutational characteristics of spinal muscular atrophy with respiratory distress type 1 in The Netherlands.
Stalpers, Xenia L.; Verrips, Aad; Poll-The, Bwee Tien et al

in Neuromuscular disorders : NMD (2013), 23(6), 461-8

Spinal muscular atrophy with respiratory distress type 1 is an autosomal recessive disorder with early respiratory difficulties, distal muscle weakness, and contractures leading to foot deformities as the ... [more ▼]

Spinal muscular atrophy with respiratory distress type 1 is an autosomal recessive disorder with early respiratory difficulties, distal muscle weakness, and contractures leading to foot deformities as the most striking clinical symptoms. Mutations of the gene encoding the immunoglobulin heavy chain mu-binding protein 2, mapped on chromosome 11q13, are the cause of the disease. We present the clinical and mutational characteristics of ten patients in the Netherlands who showed considerable clinical variability; they carried six novel mutations, including a deletion of exon 2. However, there were no clear phenotype-genotype correlations. [less ▲]

Detailed reference viewed: 11 (0 ULg)